Noble Financial Sticks to Its Buy Rating for Eyegate

By Austin Angelo

In a report issued on May 17, Mark Jordan from Noble Financial reiterated a Buy rating on Eyegate (NASDAQ: EYEG). The company’s shares closed yesterday at $1.80.

According to, Jordan is a 1-star analyst with an average return of -1.1% and a 46.9% success rate. Jordan covers the Services sector, focusing on stocks such as Information Services Group, Salem Communications Corp, and Entercom Communications.

Eyegate has an analyst consensus of Moderate Buy.

The company has a one year high of $4 and a one year low of $1.11. Currently, Eyegate has an average volume of 967.1K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

EyeGate Pharma is a clinical stage pharmaceutical company that is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. Its Products include EGP-437 and EyeGate II Delivery System. EGP-437 for the treatment of non-infectious anterior uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea, such as the iris or ciliary body. The EyeGate II Delivery System features a compact, elegant, and easy-to-use device that delivers drugs non-invasively and quickly into the ocular tissues through the use of iontophoresis, which can accelerate the onset of action, dramatically reduce treatment frequency versus eye drops and sustain therapeutic effect. The company was founded in 1998 and is headquartered in Waltham, MA.